Amylyx Pharmaceuticals Inc (AMLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 110,403 | 50,191 | 0 | 0 | 0 |
| Marketable Securities | 144,802 | 45,927 | 0 | 0 | 0 |
| Other current assets | 0 | 3,441 | 0 | 0 | 0 |
| TOTAL | $265,488 | $104,951 | $0 | $0 | $0 |
| Non-Current Assets | |||||
| PPE Net | 1,290 | 474 | N/A | N/A | N/A |
| Other Non-Current Assets | 7,660 | 189 | 0 | 0 | 0 |
| TOTAL | $8,950 | $663 | $N/A | $N/A | $N/A |
| Total Assets | $274,438 | $105,614 | $0 | $0 | $0 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 10,045 | 4,372 | 0 | 0 | 0 |
| Accrued Expenses | 16,256 | 13,024 | 0 | 0 | 0 |
| TOTAL | $27,706 | $17,396 | $0 | $0 | $0 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 5,786 | 0 | 0 | 0 | 0 |
| TOTAL | $5,786 | $35 | $N/A | $N/A | $N/A |
| Total Liabilities | $33,492 | $17,431 | $0 | $0 | $0 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 58,533 | N/A | N/A | N/A | N/A |
| Common Shares | 6 | 1 | 0 | 0 | 0 |
| Retained earnings | -203,693 | -155,845 | 0 | 0 | 0 |
| Other shareholders' equity | -151 | 239,360 | 0 | 0 | 0 |
| TOTAL | $240,946 | $88,183 | $0 | $0 | $0 |
| Total Liabilities And Equity | $274,438 | $105,614 | $0 | $0 | $0 |